Abstract Currently,whole breast radiotherapy (WBRT) is the standard treatment for early breast cancer after breast-conserving surgery, which effectively reduces the recurrence rate. Accelerated partial breast irradiation (APBI), a special radiotherapy that only targets the limited volume of tissues surrounding the primary lesion, has attracted more and more attention because of the high proportion of tumor recurrence adjacent to the tumor resection cavity. In recent years, a number of prospective randomized controlled trails have demonstrated its safety and effectiveness, which is a feasible choice for specific low-risk patients after breast-conserving surgery.compared with WBRT, APBI shortens the treatment time, reduces the treatment cost and improves the cosmetic effect. At the same time, more and more APBI technologies have been developed, which enhance the accessibility and possess unique advantages for partial patients undergoing breast-conserving surgery. Nevertheless, the efficacy and side effects of APBI technologies still differ, which need to be treated differently. In this paper, multiple APBI technologies, research progresses at home and abroad and applicable population were reviewed. The unresolved problems were proposed and development prospect was predicted, aiming to provide reference for clinical application.
Corresponding Authors:
Gan Lu, Email:ganlu99@sina.com
Cite this article:
Luo Xiaodie,Gan Lu. Research progress on accelerated partial breast irradiation for early breast cancer after breast-conserving surgery[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1321-1325.
Luo Xiaodie,Gan Lu. Research progress on accelerated partial breast irradiation for early breast cancer after breast-conserving surgery[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1321-1325.
[1] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med, 2002, 347(16):1233-1241. DOI:10.1056/NEJMoa022152. [2] van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands:a population-based study[J]. Lancet Oncol, 2016, 17(8):1158-1170. DOI:10.1016/S1470-2045(16)30067-5. [3] Clark RM,Wilkinson RH,Miceli PN, et al. Breast cancer. Experiences with conservation therapy[J]. Am J Clin Oncol, 1987, 10(6):461-468. DOI:10.1097/00000421-198712000-00001. [4] Smith TE, Lee D, Turner BC, et al. True recurrence vs. New primary ipsilateralbreast tumorrecurrences:an analysis of clinical and pathologic differences and their implications in natural history,prognoses,and therapeutic management[J]. Int J Radiat Oncol Biol Phys, 2000, 48(5):1281-1289. DOI:10.1016/s0360-3016(00)01378-x. [5] Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer:10-year follow-up results of two randomised controlled trials[J]. Lancet Oncol, 2013, 14(11):1086-1094. DOI:10.1016/S1470-2045(13)70386-3. [6] Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer:long-term results of a randomised trial[J]. Radiother Oncol, 2005, 75(1):9-17. DOI:10.1016/j.radonc.2005.01.005. [7] Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast:a randomised, phase 3, non-inferiority trial[J]. Lancet, 2016, 387(10015):229-238. DOI:10.1016/S0140-6736(15)00471-7. [8] Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer:a randomised, phase 3, equivalence trial[J]. Lancet, 2019, 394(10215):2155-2164. DOI:10.1016/S0140-6736(19)32514-0. [9] Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT):a randomised controlled equivalence trial[J]. Lancet Oncol, 2013, 14(13):1269-1277. DOI:10.1016/S1470-2045(13)70497-2. [10] Vaidya JS, Wenz F, Bulsara M, et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial)[J]. Health Technol Assess, 2016, 20(73):1-188. DOI:10.3310/hta20730. [11] Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID):a randomised controlled trial[J]. Lancet, 2019, 394(10215):2165-2172. DOI:10.1016/S0140-6736(19)32515-2. [12] Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation:5-year survival analysis of a phase 3 randomised controlled trial[J]. Eur J Cancer, 2015, 51(4):451-463. DOI:10.1016/j.ejca.2014.12.013. [13] Verma V, Shah C, Mehta MP. Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer[J]. Clin Breast Cancer, 2016, 16(3):145-154. DOI:10.1016/j.clbc.2016.02.006. [14] Hepel JT, Leonard KL, Hiatt JR, et al. Factors influencing eligibility for breast boost using noninvasive image-guided breast brachytherapy[J]. Brachytherapy, 2014, 13:579-583. DOI:10.1016/j.brachy.2014.07.003. [15] Ribeiro GG, Magee B, Swindell R, et al. The Christie Hospital breast conservation trial:an update at 8 years from inception[J]. Clin Oncol, 1993, 5(5):278-283. DOI:10.1016/s0936-6555(05)80900-8. [16] Polgár C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation:ten-year results of the Budapest randomized trial[J]. Radiother Oncol, 2013, 108(2):197-202. DOI:10.1016/j.radonc.2013.05.008. [17] Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial):5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial[J]. Lancet, 2017, 390(10099):1048-1060. DOI:10.1016/S0140-6736(17)31145-5. [18] Vaidya JS, Bulsara M, Saunders C, et al. Effect of delayed targeted intraoperative radiotherapy vs. whole-breast radiotherapy on local recurrence and survival long-term results from the TARGIT-A randomized clinical trial in early breast cancer[J]. JAMA Oncol, 2020,6(7):e200249. DOI:10.1001/jamaoncol.2020.0249. [19] Yoshida K, Nose T, Masuda N, et al. Preliminary result of accelerated partial breast irradiation after breast-conserving surgery[J]. Breast Cancer, 2009, 16(2):105-112. DOI:10.1007/s12282-008-0067-7. [20] Koh YV, Tan PW, Buhari SA, et al. Accelerated partial breast irradiation in an Asian population:dosimetric findings and preliminary results of a multicatheter interstitial program[J]. Onco Targets Ther, 2016, 9:5561-5566. DOI:10.2147/OTT. S106758. [21] Li FY, He ZY, Xue M, et al. Feasibility and acute toxicity of 3-dimensional conformal external-beam accelerated partial-breast irradiation for early-stage breast cancer after breast-conserving surgery in Chinese female patients[J]. Chin Med J, 2011, 124(9):1305-1309. DOI:10.3760/cma.j.issn.0366-6999.2011.09.006. [22] 李永恒,铁剑,吴昊,等. 早期乳腺癌保乳术后部分乳腺快速调强放疗26例临床观察[J]. 中华医学杂志,2013, 93(12):924-926. DOI:10.3760/cma.j.issn.0376-2491.2013.12.011. Li YH, Tie J, Wu H, et al. Clinical observation of accelerated partial-breast intensity-modulated radiotherapy in patients with early-stage breast cancer after breast-conserving surgery[J]. Chin Med J, 2013, 93(12):924-926. DOI:10.3760/cma.j.issn.0376-2491.2013.12.011. [23] Polgár C, Van Limbergenb E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery:recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J]. Radiother Oncol, 2010, 94(3):264-273. DOI:10.1016/j.radonc.2010.01.014. [24] Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation:executive summary for the update of an ASTRO evidence-based consensus statement[J]. Pract Radiat Oncol, 2017, 7(2):73-79. DOI:10.1016/j.prro.2016.09.007. [25] Shah C, Vicini F, Shaitelman SF, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation[J]. Brachytherapy, 2018, 17(1):154-170. DOI:10.1016/j.brachy.2017.09.004. [26] American Society of Breast Surgeons. Consensus guideline on accelerated partial breast irradiation[EB/OL][2020-09-01].https://www.breastsurgeons.org.
2021, Vol. 30 
